SOCS1 is upregulated when a cytokine binds to its cognate receptor, and in turn SOCS1 inhibits JAK activity by binding to its catalytic domain and recruiting the ubiquitin-transferase complex to target JAK for proteasomal degradation, leading to inactivation of JAK-related signaling and inhibition of tumor cell growth [39]. The gene discussed is SOCS1; the disease is neoplasm.